Role of Intracoronary Adenosine on Prevention of No Reflow during Primary PCI in STEMI Patients Guided by MVO in CMR | ||||
| Cardiovascular Research Prove Journal | ||||
| Volume 6, Issue 1, June 2022 PDF (119.87 K) | ||||
| Document Type: Abstracts | ||||
| DOI: 10.21608/cvrepj.2022.351472 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Microvascular obstruction (MO) or no-reflow phenomenon is an established complication of coronary reperfusion therapy for acute myocardial infarction. It is increasingly recognized as a poor prognostic indicator and marker of subsequent adverse LV remodeling. Microvascular obstruction (MO) or no-reflow phenomenon is an established complication of coronary reperfusion therapy for acute myocardial infarction. It is increasingly recognized as a poor prognostic indicator and marker of subsequent adverse LV remodeling. | ||||
|
Statistics Article View: 60 PDF Download: 24 |
||||
